Breaking News

Tris Pharma Appoints New BD VP

November 15, 2012

Berlent brings extensive industry experience

Jonathan Berlent has been appointed vice president of business development at Tris Pharma. He will lead the company’s product and technology partnering, and collaborate with branded pharmaceutical companies on their life cycle management opportunities.
“As Tris scales up its effort to address the growing unmet need in the industry for liquid extended release technology, Jonathan will lead business development efforts and be our point person with branded pharmaceutical companies,” said Ketan Mehta, president and chief executive officer of Tris Pharma.
Mr. Berlent has a combination of pharmaceutical and securities industry experience. For the past nine years, he has held various senior leadership positions in the pharmaceutical industry. Most recently, he was president of Granules USA, where he led its North American operations and successfully launched a finished dosage business platform, working with companies including Pfizer, Novartis, McNeil Consumer Health Janssen, GlaxoSmithKline, Par and Perrigo.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks